Jones Hill Capital
Latest statistics and disclosures from Jones Hill Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are BMRN, GILD, ARQT, MDGL, BCAX, and represent 44.34% of Jones Hill Capital's stock portfolio.
- Added to shares of these 10 stocks: GILD (+$43M), ARQT (+$29M), MDGL (+$28M), RLMD (+$23M), XENE (+$22M), TRVI (+$18M), PHVS (+$18M), IMCR (+$16M), INSM (+$13M), BMRN (+$9.3M).
- Started 15 new stock positions in XENE, GILD, ARQT, INSM, OLMA, CRBP, ACHV, SNDX, IMCR, ACRS. PHAT, IMUX, ORIC, DNTH, MDGL.
- Reduced shares in these 10 stocks: VRTX (-$48M), PCVX (-$38M), ELVN (-$28M), TERN (-$28M), NUVL (-$25M), RARE (-$24M), ARGX (-$19M), FULC (-$14M), AMLX (-$13M), CAPR (-$12M).
- Sold out of its positions in ARGX, AVBP, CTNM, TRDA, FULC, NUVB, ORKA, SLN, TERN, RARE. PCVX, MANE.
- Jones Hill Capital was a net seller of stock by $-36M.
- Jones Hill Capital has $470M in assets under management (AUM), dropping by 0.83%.
- Central Index Key (CIK): 0002102314
Tip: Access up to 7 years of quarterly data
Positions held by Jones Hill Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Jones Hill Capital
Jones Hill Capital holds 29 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| BioMarin Pharmaceutical (BMRN) | 17.4 | $82M | +12% | 1.4M | 57.22 |
|
| Gilead Sciences (GILD) | 9.2 | $43M | NEW | 343k | 126.34 |
|
| Arcutis Biotherapeutics (ARQT) | 6.1 | $29M | NEW | 1.1M | 26.22 |
|
| Madrigal Pharmaceuticals (MDGL) | 6.0 | $28M | NEW | 53k | 536.95 |
|
| Bicara Therapeutics (BCAX) | 5.6 | $27M | -29% | 893k | 29.69 |
|
| Relmada Therapeutics (RLMD) | 5.4 | $25M | +966% | 3.7M | 6.92 |
|
| Trevi Therapeutics (TRVI) | 5.3 | $25M | +261% | 1.3M | 18.65 |
|
| Pharvaris N V (PHVS) | 5.0 | $23M | +305% | 678k | 34.58 |
|
| Xenon Pharmaceuticals (XENE) | 4.7 | $22M | NEW | 368k | 60.36 |
|
| Biosante Pharmaceuticals (ANIP) | 4.1 | $19M | -26% | 234k | 82.78 |
|
| Immunocore Hldgs Ads (IMCR) | 3.5 | $16M | NEW | 513k | 31.75 |
|
| Amylyx Pharmaceuticals (AMLX) | 3.4 | $16M | -44% | 894k | 17.96 |
|
| Insmed Com Par $.01 (INSM) | 2.8 | $13M | NEW | 122k | 106.62 |
|
| Nuvalent Inc-a (NUVL) | 2.6 | $12M | -67% | 98k | 123.50 |
|
| Capricor Therapeutics Com New (CAPR) | 2.2 | $10M | -53% | 421k | 24.08 |
|
| Aclaris Therapeutics (ACRS) | 2.0 | $9.3M | NEW | 1.8M | 5.29 |
|
| Immunic Com New (IMUX) | 1.8 | $8.3M | NEW | 540k | 15.37 |
|
| Oric Pharmaceuticals (ORIC) | 1.7 | $8.1M | NEW | 747k | 10.83 |
|
| Tonix Pharmaceuticals Hldg C Com New (TNXP) | 1.7 | $8.0M | +38% | 625k | 12.76 |
|
| Syndax Pharmaceuticals (SNDX) | 1.6 | $7.4M | NEW | 340k | 21.86 |
|
| Olema Pharmaceuticals (OLMA) | 1.5 | $7.2M | NEW | 574k | 12.51 |
|
| Vir Biotechnology (VIR) | 1.4 | $6.7M | -44% | 659k | 10.19 |
|
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 1.3 | $6.1M | NEW | 654k | 9.38 |
|
| Dianthus Therapeutics (DNTH) | 1.2 | $5.6M | NEW | 57k | 97.48 |
|
| Vertex Pharmaceuticals Incorporated (VRTX) | 1.2 | $5.5M | -89% | 11k | 496.73 |
|
| Enliven Therapeutics (ELVN) | 0.5 | $2.5M | -91% | 50k | 50.75 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 0.5 | $2.2M | -59% | 41k | 53.67 |
|
| Phathom Pharmaceuticals (PHAT) | 0.4 | $1.8M | NEW | 162k | 10.85 |
|
| Achieve Life Sciences (ACHV) | 0.0 | $175k | NEW | 27k | 6.53 |
|
Past Filings by Jones Hill Capital
SEC 13F filings are viewable for Jones Hill Capital going back to 2026
- Jones Hill Capital 2026 Q2 filed Aug. 13, 2026
- Jones Hill Capital 2026 Q1 filed May 14, 2026